1. Home
  2. IBRX vs NVG Comparison

IBRX vs NVG Comparison

Compare IBRX & NVG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ImmunityBio Inc.

IBRX

ImmunityBio Inc.

HOLD

Current Price

$2.05

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Logo Nuveen AMT-Free Municipal Credit Income Fund

NVG

Nuveen AMT-Free Municipal Credit Income Fund

HOLD

Current Price

$12.67

Market Cap

2.7B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
IBRX
NVG
Founded
2014
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.7B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
IBRX
NVG
Price
$2.05
$12.67
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$9.71
N/A
AVG Volume (30 Days)
13.6M
568.8K
Earning Date
11-04-2025
01-01-0001
Dividend Yield
N/A
4.65%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$82,555,000.00
N/A
Revenue This Year
$667.18
N/A
Revenue Next Year
$93.03
N/A
P/E Ratio
N/A
N/A
Revenue Growth
1025.95
N/A
52 Week Low
$1.83
$9.68
52 Week High
$4.27
$12.21

Technical Indicators

Market Signals
Indicator
IBRX
NVG
Relative Strength Index (RSI) 45.08 58.09
Support Level $1.95 $12.46
Resistance Level $2.29 $12.70
Average True Range (ATR) 0.12 0.08
MACD -0.02 0.01
Stochastic Oscillator 19.09 75.45

Price Performance

Historical Comparison
IBRX
NVG

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

About NVG Nuveen AMT-Free Municipal Credit Income Fund

Nuveen AMT-Free Municipal Credit Income Fund is a diversified, closed-end management investment company. Its objective is to provide current income exempt from regular federal income tax and federal alternative minimum tax applicable to individuals and enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the investment adviser believes are underrated or undervalued or represent undervalued municipal market sectors.

Share on Social Networks: